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Glucocorticoids (GCs) act via the glucocorticoid receptor (NR3C1, GRα) to combat
overshooting responses to infectious stimuli, including lipopolysaccharide (LPS). As
such, GCs inhibit the activity of downstream effector cytokines, such as tumor necrosis
factor (TNF). PPARα (NR1C1) is a nuclear receptor described to function on the
crossroad between lipid metabolism and control of inflammation. In the current work,
we have investigated the molecular mechanism by which GCs and PPARα agonists
cooperate to jointly inhibit NF-κB-driven expression in A549 cells. We discovered a
nuclear mechanism that predominantly targets Mitogen- and Stress-activated protein
Kinase-1 activation upon co-triggering GRα and PPARα. In vitro GST-pull down
data further support that the anti-inflammatory mechanism may additionally involve a
non-competitive physical interaction between the p65 subunit of NF-κB, GRα, and
PPARα. Finally, to study metabolic effector target cells common to both receptors,
we overlaid the effect of GRα and PPARα crosstalk in mouse primary hepatocytes
under LPS-induced inflammatory conditions on a genome-wide level. RNA-seq results
revealed lipid metabolism genes that were upregulated and inflammatory genes that
were additively downregulated. Validation at the cytokine protein level finally supported a
consistent additive anti-inflammatory response in hepatocytes.
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INTRODUCTION
Glucocorticoid hormones (GCs) are the mainstay of treatment for most inflammatory and
autoimmune diseases (1, 2). GCs also regulate glucose and fat homeostasis, however a long-term
therapeutic treatment with exogenous GCs causes hyperglycaemia, insulin resistance and disturbed
fat profiles as clinically worrying drawbacks (3). A reduction in adverse effects related to glucose and
fat regulation would be highly desirable in clinical GC applications.
Therapeutic activities of GCs are mediated by the glucocorticoid receptor (NR3C1) (4),
belonging to the superfamily of ligand-inducible transcription factors (4). Unliganded GR
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predominantly resides in the cytosol in an inactive state
associated with heat shock proteins (HSPs) and immunophilins
(4, 5). Upon GC binding, GR translocates to the nucleus
and binds to GR binding sequences (GBSs), widely dispersed
throughout the genome (6). These may include enhancers,
hot spots, as well as GC-response elements (GREs) within
the promoter regions of target genes, hereby regulating their
transcriptional activity (7–10). Additionally, transcriptional
regulation mediated by the GR also encompasses inhibitory
effects on the activity of pro-inflammatory transcription factors
driving the onset of inflammation, such as nuclear factor-κB
(NF-κB), resulting in pro-inflammatory gene suppression (11–
13). Throughout the years, many different mechanisms have
been proposed explaining how GR inhibits pro-inflammatory
gene expression, including direct mechanisms as well as
feedback loop mechanisms by GC-induced anti-inflammatory
proteins (14, 15). Suggestive of conserved mechanisms among
nuclear receptors, the fibrate ligand-activated transcription factor
peroxisome proliferator-activated receptor α (PPARα), a member
of the nuclear hormone receptor superfamily, may also exert
anti-inflammatory actions by down-regulating the activity of
NF-κB and other pro-inflammatory transcription factors via
multiple mechanisms, with some reminiscent of the ones GR is
deploying (16, 17).
In addition, both GR and PPARα exhibit overlapping and
complementary roles in liver with regard to carbohydrate and fat
metabolism (13, 18) and co-ordinately control key genes involved
in the maintenance of blood glucose levels, cooperatively support
fatty acid β-oxidation during fasting, and stimulate immune
suppression (19–21).
We previously reported that GRα and PPARα, when co-
activated, physically interact in vitro and in cellulo, in the nucleus
(22), paving the way for an extra level of gene regulatory
mechanisms apart from triggering their own cognate gene
programs. PPARα activation further enhanced GR-triggered
suppression of TNF-induced NF-κB-driven gene expression and
pro-inflammatory cytokine production in fibroblast (L929sA)
cells (22). PPARα activation also suppressed GR-induced
upregulation of G6PC (22), one of the metabolic genes
responsible for adverse effects related to glucose metabolism
upon chronic GC therapy. Mice subjected to a 7-week high fat
diet and that received a daily administration of the synthetic
GC Dexamethasone (DEX) for another 7 days instead of
solvent, demonstrated a worsened glucose intolerance which
coincided with enhanced hyperinsulinemia. Oppositely, high fat
diet fat mice receiving the PPARα agonist fenofibrate (FENO)
for 7 days supported clear glucose tolerance. Remarkably, the
latter phenotype was also observed when combining DEX
with FENO, indicating crosstalk and a potential advantage at
the glucose metabolism level when combining two nuclear
receptor ligands for which anti-inflammatory actions had been
demonstrated (22). Collectively, these results justify further
mechanistic exploration of a combination of GCs with PPARα
agonists in a context of inflammation, starting with simple cell
models to understand first the cell-autonomous crosstalk modes
in more detail.
Mitogen- and Stress-activated protein Kinase-1 (MSK1) is a
kinase that acts, among others, in the TNF-signaling pathway.
It promotes inflammatory gene transcription by phosphorylating
NF-κB, which facilitates association of p65 with cofactors, and
by phosphorylating histone H3 (23–25). We previously reported
that GCs counteract MSK1 recruitment at inflammatory gene
promoters and partially drive MSK1 to the cytoplasm, as a
contributory mechanism to inhibit NF-κB transactivation (23).
Crosstalk between GCs and MAPK signaling pathways was
considered before as a valid mechanism to effectively inhibit NF-
κB-driven inflammatory gene promoters (26). PPARα agonists
have also been shown to modulate MAPK activities, indirectly
suppressing inflammatory responses (27, 28). As we previously
observed no significant inhibitory effect of GCs on p38 and
ERK MAPK activation in L929sA mouse fibroblasts (29) and
A549 human epithelial cells (23), we explored whether in
A549 human epithelial cells combined treatment of GCs and
PPARα agonists might target the more downstream kinase MSK1
and thus might contribute to the additive transrepression of
NF-κB-driven inflammatory genes observed when triggering
both receptors.
In the present research we overlaid a mechanistic study
of the effect of GR and PPARα crosstalk under TNF-induced
inflammatory conditions in A549 human epithelial cells as a
first cellular model system for inflammatory responses, with a
genome-wide impact of combined ligand treatment in metabolic
effector cells using LPS-induced primary hepatocytes as a
second, complementing, model system. RNA-seq results in
primary hepatocytes revealed inflammatory genes that were
synergistically downregulated and lipid metabolism genes that
were additively upregulated following the activation of both
nuclear receptors. In addition, our data reveal that, upon co-
triggering of GRα and PPARα, a nuclear anti-inflammatory
mechanism may follow from a hampering at the level of
TNF-activated kinase MSK1 activation in a lung epithelial
cell line. Taken together, our findings unveil novel molecular
aspects of the PPARα-GR-mediated NF-κB-targeting anti-
inflammatory mechanism.
MATERIALS AND METHODS
Cytokines, Plasmids, and Reagents
Dexamethasone (D4902) (DEX) and GW7647 (G6793) (GW)
were obtained from Sigma–Aldrich (St. Louis, MO, USA). Anti-
GR, anti-PPARα, anti-RNA pol II and anti-p65 antibodies were
obtained from Santa Cruz. Phospho-specific rabbit antibodies
to p38 (Thr-180/Tyr-182), p42/44 ERK (Thr202/Tyr204), MSK1
(Thr581) and IKKα/β (Ser180/S181) were used to detect
the respective phosphorylated forms and purchased from
Cell Signaling. Anti-p38, anti-ERK, anti-MSK1, and anti-IκBα
antibodies were purchased from Cell Signaling. Anti-tubulin
and anti-actin were used as loading control and obtained
from Santa Cruz. Anti-phospho-65 was obtained from Santa
Cruz. Recombinant murine TNFα was produced and purified
as described (30). TNFα was used at a final concentration of
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2,000 IU/ml. p(IL6κB)350hu.IL6P-luc+ (hereafter renamed NF-
κB-Luc), PPARα, GR, and 5HT7 control plasmids were described
previously (21, 31–33). LPS was purchased from Invivogen.
Cell Culture
A549 cells were grown in DMEM plus 10% fetal calf serum,
100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were
maintained in a 5% CO2-humidified atmosphere at 37
◦C.
Transfection and Reporter Assays
A549 cells were transiently transfected using Lipofectamine and
PLUS reagents, as described by the manufacturer (Invitrogen,
Life Technologies). In short, cells within each well of a 24-well
plate were transfected using 400 ng DNA, 1.2 µl lipofectamine
and 0.8 µl PLUS reagent. After 5 h incubation with the
transfection reagent, the medium was refreshed with standard
culture medium (see above). After transfection, cells were left
to rest for another 24 h before inductions. Cells were induced
as indicated in the figure legends, after which luciferase assays
were carried out according to instructions of the manufacturer
(Promega). Luciferase measurements were performed at least
in triplicate and normalized by measurement of β-galactosidase
levels using the Galacto-Light kit (Tropix). Results presented are
from 3 independent biological replicates.
Western Analysis
Total cell lysates were prepared using 1 × SDS sample buffer
(50mM Tris pH 6.8; 2% SDS; 10% glycerol; bromophenol blue
and 100mM DTT, freshly added). Samples were incubated
at 95◦C for 5min and separated on a SDS-PAGE gel
and subsequently blotted onto a Nitrocellulose membrane
(Whatman, Dassel, Germany). Immunoblotting was performed
according to the standard protocol of Santa Cruz (Santa Cruz,
CA, USA). Imaging of antibody-tagged protein signal was
obtained via Western Lightning (PerkinElmer, Waltham, MA,
USA). To quantify bands obtained via Western analysis, we
applied band densitometric analysis via ImageJ software (http://
rsb.info.nih.gov/ij/). The area under curve (AUC) of the specific
signal of the protein of interest as indicated in the figure legend
was corrected for the AUC of the loading control, indicated in the
figure legend. Results representative of 2 independent biological
repeats are shown.
Immunofluorescence
Indirect immunofluorescence was performed as previously
described (34). In short, A549 cells, seeded on coverslips and
serum-deprived for 48 h, were induced as indicated in the
figure legends. After fixation, endogenous p65 and MSK1 were
visualized using the corresponding rabbit antibodies followed by
Alexa Fluor 488 or Alexa Fluor 568 anti-rabbit IgG (Molecular
Probes, Invitrogen). Endogenous PPARα was visualized using
the corresponding goat antibody followed by Alexa Fluor
488 anti-goat IgG (Molecular Probes, Invitrogen). Endogenous
GRα was visualized using the corresponding mouse antibody
followed by Alexa Fluor 568 anti-mouse IgG (Molecular Probes,
Invitrogen). Cell nuclei were stained using DAPI DNA staining
(300 nM, Invitrogen).
FIGURE 1 | GCs and PPARα agonists inhibit pro-inflammatory gene expression in A549 cells. (A) A549 cells were pre-incubated with solvent, DEX (1µM), GW
(0.5µM) or various combinations thereof, for 1 h, before TNF (2000 IU/ml) was added, where indicated, for a total induction time of 6 h. mRNA was isolated, reverse
transcribed, and subjected to QPCR using primers to detect IL8. qPCR measurements were performed in triplicates. qPCR results, normalized to expression of
household genes, are shown ± SD. (B) A549 cells were transiently transfected with NF-κB-Luc using Lipofectamine/Plus reagents, as described (Invitrogen,
Carlsbad, CA, USA). 24 h after transfection, cells were incubated with solvent, DEX (0.1 or 1µM), GW (0.25, 0.5, or 1µM) or various combinations thereof, for 1 h,
before TNF (2000 IU/ml) was added, where indicated, for a total induction time of 6 h. Cell lysates were assayed for luc activities and normalized with β-gal activities.
Promoter activities are expressed as relative induction factor calculated as percentage of maximal TNF response. Results in (A,B) are from three independent
biological replicates (n = 3) with measurements in triplicate. Statistical analysis was done using ANOVA with Tukey’s multiple comparison post-test (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
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In vitro Protein-Protein Interaction Assay
(GST Pull-Down)
GST-fusion proteins with PPARα and 5HT7 were expressed
in BL21 bacterial cells and purified with glutathione-agarose
beads. GRα and p65 proteins were transcribed and translated
in vitro using the TNT T7-coupled reticulocyte lysate system
(Promega) according to the manufacturer’s instructions. GST
pull-down was carried out by incubating the equivalent of 2
µg of GST-PPARα beads with 10 µl of in vitro translated
[35S]-methionine labeled GRα with increasing amounts of non-
labeled GRα, or by incubating the equivalent of 2 µg of GST-
PPARα beads with 10 µl of [35S]-methionine labeled p65 with
increasing amounts of [35S]-methionine labeled GRα or finally,
by incubating the equivalent of 2 µg of GST-PPARα beads with
10 µl of [35S]-methionine labeled GRα with increasing amounts
of [35S]-methionine labeled p65. All of these interaction studies
were performed in a total volume of 200 µl of incubation
buffer [20mM Tris-HCl (pH 8), 300mM NaCl, 6mM MgCl2,
8% glycerol, 0.05% Nonidet P-40, 0.1% dithiothreitol]. The
mixture was gently rotated for 2 h at 4◦C. After centrifugation,
the beads were washed five times with incubation buffer
supplemented with NaCl up to a final concentration of 500mM,
next resuspended in 25 µl of 1x Laemmli buffer, boiled for
3min, and centrifuged. After GST-mediated purification and
extensive washes, proteins were separated on polyacrylamide gels
and visualized by autoradiography. GST-5HT7 was used as a
negative control.
Primary Hepatocyte Isolation
Primary hepatocytes were isolated from 10 to 12 week-old male
C57BL/6 mice by collagenase perfusion (35). The procedure
was modified by excluding insulin and DEX supplementation
in the William’s medium (Sigma, W1878), but keeping 0.1%
free-fatty acids and 1% glutamine. After isolation cells were
seeded on collagen-coated 6-well plates at a density of
0.75 × 106 cells. After 2 h of attachment medium was
refreshed and ligands were introduced, as indicated in the
figure legends.
qPCR and ChIP-qPCR
RNA was isolated with the RNeasy purification kit (Qiagen)
according to the user manual. cDNA was synthesized with
a PrimeScript kit (Takara). qPCR was performed using Light
Cycler 480 SYBR Green I Master Mix (Roche). The primer
list is provided in Table S1. qPCR data were normalized and
quantified relative to the 2 most stable reference genes with
qbase+ (36). ChIP assays were performed as previously described
(37). The relative amount of the precipitated target sequence was
determined via normalization to the “input”, i.e., the purified
total gDNA levels. The primers for IL8, encompassing−121/+61,
have been described earlier (38).
RNA-Seq Analysis
RNA-seq was done in three biological replicates. Each replicate
was obtained by pooling cells from 3 to 4 mice and then
performing induction in three technical replicates. RNA was
isolated with the RNeasy purification kit (Qiagen) according
to the user manual. Library preparation and sequencing was
prepared by the VIB Nucleomics Core facility. 75 bp long
sequenced reads were generated with Illumina NextSeq 500 and
were mapped to the mm10 genome using tophat (version 2.0.11).
Gene counts were calculated with htseq-count (0.6.1) using
“intersection-strict” mode. Gene level differential expression
analysis was performed with the aid of the R package “DESeq2”
by applying the following contrasts (p adjusted < 0.05): LPS
FIGURE 2 | Co-activation of GRα and PPARα does not affect pathways
influencing the nuclear accumulation of activated p65. (A) A549 cells, starved
for 48 h in DMEM devoid of serum, were pretreated with solvent, DEX (1µM),
GW (0.5µM) or various combinations for 1 h, before TNF (2000 IU/ml) was
added, where indicated, for 30min. Cell lysates were subjected to western
blotting using anti-phospho-IKK or anti-IκBα antibodies, and using anti-tubulin
as a loading control, as indicated. A representative blot of n = 2 is shown. (B)
A549 cells were treated with DEX (1µM) and/or GW (0.5µM) and/or TNF
(2000 IU/ml). Indirect immunofluorescence was performed using an anti-p65
antibody. Endogenous p65 was visualized (green), DAPI staining indicates the
nuclei of the cells (blue) and “Overlay” shows a merged image with both
stainings combined. Representative images of n = 2 are shown. (C) Per
induction, minimally three random fields of minimally 5 cells/field were scored.
Scored cells are categorized into three groups according to the subcellular
distribution of p65, i.e., C, mainly cytoplasmic; N, mainly nuclear; N/C, equally
distributed (nuclear/cytoplasmic) with % distribution presented as pie charts.
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vs. DEX+LPS, LPS vs. GW+LPS, LPS vs. DEX/GW+LPS,
DEX+LPS vs. DEX/GW+LPS andGW+LPS vs. DEX/GW+LPS.
Differentially expressed genes were combined into a single list
and re-ordered using a K-mean clustering (6 clusters). Gene
ontology analysis of gene clusters 2, 3, and 5 was performed using
“goseq” R package.
ELISA
CCL2 and IL6 ELISA was performed on media
from primary hepatocytes after 19 h induction with
compounds DEX and/or GW in combination with
100 ng/ml LPS by using the ELISA MAX Standard
(BioLegend, 432702, 430502), in according with
the manual.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
software (version 7.02 or 8). Significant differences between
groups were evaluated using two-way (2 factors) ANOVA
with Dunnett’s test for multiple comparison, which was
found to be appropriate as groups displayed a normal
FIGURE 3 | Co-activation of GRα and PPARα efficiently lowers levels of phospho-MSK-1 in A549. (A) A549 cells, starved for 48 h in DMEM devoid of serum, were
pretreated with solvent, DEX (1µM), GW (0.5µM) or various combinations for 1 h, before TNF (2000 IU/ml) was added, where indicated, for 30min. Cell lysates were
subjected to western blotting with anti-phospho-MAPK and the corresponding non-phospho antibodies; for this re-probed blot the same overall loading control
applies as shown in Figure 2A. A representative blot of n = 2 is shown. (B) A549 cells, starved for 48 h in DMEM devoid of serum, were pretreated with solvent, DEX
(1µM), GW (0.5µM) or various combinations for 1 h, before TNF (2000 IU/ml) was added, where indicated, for 15min and 30min. Cell lysates were subjected to
western blotting with anti-phospho-MSK1, anti-MSK1 and anti-actin as a loading control, as indicated. A representative blot of n = 2 is shown. (C) A549 cells were
treated with DEX (1µM) and/or GW (0.5µM) and/or TNF (2000 IU/ml) for 30min. Indirect immunofluorescence was performed using an anti-MSK1 antibody.
Endogenous MSK1 was visualized (green), DAPI staining indicates the nuclei of the cells (blue) and Overlay indicates an image of both stainings combined.
Representative images of n = 2 are shown. (D) Per induction, minimally three random fields of minimally 5 cells/field were scored. Scored cells are categorized into
three groups according to the subcellular distribution of MSK1, i.e., C, mainly cytoplasmic; N, mainly nuclear; N/C, equally distributed (nuclear/cytoplasmic) with %
distribution presented as pie charts.
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distribution. Normality was tested with the D’Agostino-
Pearson normality test. When variances across groups were
not equal, logarithmic transformation was applied prior to
statistical analysis. Values are expressed as mean + SEM,
and error bars were derived from biological replicates
rather than technical replicates. p < 0.05 was considered
statistically significant.
RESULTS
GCs and PPARα Agonists Inhibit
Pro-inflammatory Gene Expression in a
Concentration-Responsive Manner
We first verified, using A549 lung epithelial cells, that the
single PPARα agonist GW7647 (hereafter GW) and the single
FIGURE 4 | Ligand-activated GRα and PPARα are both localized in the nucleus in TNF-stimulated cells. (A) A549 cells, starved for 48h in DMEM devoid of serum,
were pretreated with solvent, DEX (1µM), GW (0.5µM) or various combinations for 1h, before TNF (2000 IU/ml) was added, where indicated, for 30min. Localization
of PPARα (green) and GRα (red) was assessed by confocal analysis. DAPI staining indicates the nuclei of the cells (blue). Immunofluorescence of representative cell
fields are shown (n = 1). (B) Per induction, minimally three random fields of minimally 5 cells/field were scored. Scored cells are categorized into three groups
according to the subcellular distribution of PPARα (green) and GRα (red), i.e., C, mainly cytoplasmic; N, mainly nuclear; N/C, equally distributed (nuclear/cytoplasmic).
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synthetic GR agonist dexamethasone (DEX) are both able to
inhibit TNF-induced gene expression (Figure 1A, lanes 6 and
7 compared to lane 5). We go on to show that an additive
anti-inflammatory effect can be observed for a complex NF-κB-
driven promoter in its endogenous promoter context, i.e., TNF-
induced IL-8 mRNA expression (Figure 1A, lane 8 compared to
lanes 6 and 7). Results from A549 cells transiently transfected
with a recombinant NF-κB-driven promoter construct as a direct
transcriptional read-out (Figure 1B) confirm TNF-induced NF-
κB as a relevant nuclear receptor target and show anti-
inflammatory effects by single DEX and GW, in a concentration-
responsive manner (Figure 1B, lanes 8 to 10 and lanes 11
and 15 compared to lane 7). Combined DEX/GW treatment
results in an additive repression of TNF-induced recombinant
NF-κB promoter activity when compared to compound alone
(Figure 1B, lanes 12 to 14 compared to lane 11 and lanes 16–
18, compared to lane 15) even when using saturating amounts
of DEX. Taken together, these data support our previous findings
in L929sA where the additive anti-inflammatory effect of DEX
and GW also converged on NF-κB (22). Collectively, these results
raise the question whether combined ligand treatment may
act differently on components of the upstream cascade leading
toward NF-κB or may differently impinge on NF-κB binding
or activity.
Co-activation of GRα and PPARα Does Not
Affect the Upstream TNF-Induced IKK
Activation Pathway or the Nuclear
Accumulation of Activated p65
To first test whether the TNF-induced kinase cascade upstream
of the activity of p65 can be a target of a GRα and PPARα-
mediated inhibition, we evaluated levels of activated IKK and
the inhibitory protein of NF-κB. IκBα is known to be degraded
following activation of IKK and subsequent phosphorylation
upon an inflammatory stimulus, e.g., TNFα. This was confirmed
in Figure 2A (for quantification please see Figure S1). No
significant effect of DEX, GW or the combination hereof was
apparent on TNF-activated IKK (Figure 2A). In line with these
results, DEX and GW also did not affect the TNFα-induced
nuclear translocation of the p65 subunit of NF-κB as shown
by indirect immunofluorescence analysis (Figure 2B). Based
on these results, the cooperative anti-inflammatory activity
of GCs and PPARα agonists most likely operates within the
cellular nucleus.
Co-activation of GRα and PPARα Does Not
Affect MAPK Activation but Efficiently
Lowers Levels of Phospho-MSK-1 in A549
As we observed no significant inhibitory effect of combined
DEX/GW treatment on the above-mentioned kinases in Figure 2,
we further explored whether combined treatment of GCs
and PPARα agonist might target TNF-induced phospho-
ERK, phospho-JNK and phospho-p38 or the downstream
nuclear kinase MSK1 (Figure 3). As shown in Figure 3A,
none of the TNF-activated MAPK is differentially affected
comparing GC/PPARα co-treatment with single treatments
(for quantification please see Figure S2A). However, compared
to each compound alone, co-treatment with the PPARα
agonist GW and DEX clearly reduces the TNF-induced MSK1
phosphorylation, apparent at 15min (Figure 3B, upper panel)
and at 30min (Figure 3B, lower panel) (for quantification
please see Figure S2B). In line with our previous results (23),
DEX is able to partially extrude TNF-induced MSK1 from the
nucleus (Figure 3C). Both GW alone as well as the combination
DEX/GW yields a similar result when combined with TNF, as
FIGURE 5 | Combined DEX and PPARα agonist treatment maintains chromatin recruitment of TNF-activated p65. Following serum starvation for 48 h, A549 cells
were pre-incubated with solvent, DEX (1µM), GW (0.5µM) or various combinations for 1 h, before TNF (2000 IU/ml) was added, where indicated, for 30min.
Cross-linked and sonicated cell lysates were subjected to ChIP analysis against p65 (A), GR (B) or RNA pol II (C). qPCR was used to assay recruitment at the IL8
gene promoter. The quantity of p65, GR or RNA pol II detected at the IL8 promoter is shown with a correction of the SYBR green qPCR signal for input control. Lanes
1–8 contain data derived from DNA pulled with specific antibody-prepared ChIPs, as indicated in the graph; lane 9 includes the IgG control. The reaction was
performed in triplicate. Results are compiled from three independent biological replicates (n = 3). Statistical analysis was done using ANOVA with Tukey’s multiple
comparison post-test. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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compared to TNF alone (Figure 3C). From the cell counts it
is clear that combined DEX/GW with TNF recapitulates the
same phenotype as observed for DEX/TNF (Figure 3D). Still, in
all combinations a predominant nuclear MSK1 signal remains.
Taken together, these results suggest that the combined inhibitory
effect of GCs and PPARα agonists on phosphorylated MSK1
may contribute to the additive transrepression of NF-κB-driven
inflammatory genes triggered by activated GR and PPARα.
Ligand-Activated GRα and PPARα Are Both
Localized in the Nucleus in TNF-Stimulated
A549 Cells
Wenext wondered whether the activated nuclear receptors would
remain nuclear in absence and presence of TNF. Endogenous
co-immunolocalization analyses show that under conditions in
which p65 is activated upon TNF (Figures S3, S4) and under
conditions when both GRα and PPARα are activated, the
FIGURE 6 | PPARα and GRα interact with NF-κB p65, in a non-competitive
manner in vitro. GST-fusion proteins PPARα and 5HT7 were expressed in
BL21 bacterial cells and purified with glutathione-agarose beads.
[S35]-methionine labeled GRα and or p65 products were generated with TNT
reaction, using rabbit reticulocyte lysates. (A) [35S]-methionine labeled GRα
was incubated with Glutathione-Sepharose 4B beads loaded with GST-PPARα
or GST-5HT7 as control with increasing amount of non-labeled GRα. (B)
[35S]-methionine labeled p65 was incubated with Glutathione-Sepharose 4B
beads loaded with GST-PPARα or GST-5HT7 as control with increasing
amount of [35S]-methionine labeled GRα. (C) [35S]-methionine labeled GRα
was incubated with Glutathione-Sepharose 4B beads loaded with GST-PPARα
or GST-5HT7 as control with increasing amount of [35S]-methionine labeled
p65. Representative images of n = 2 are shown.
latter proteins effectively reside predominantly in the nuclear
compartment (Figure 4).
Combined DEX and PPARα Agonist
Treatment Maintains Chromatin
Recruitment of TNF-Activated p65
To next study the impact of single vs. combined ligand treatment
on the subsequent binding behavior of NF-κB we analyzed the
IL8 promoter nearby the promoter proximal NF-κB binding
site, using chromatin immunoprecipitation (ChIP) analysis. The
results in Figure 5A show that the PPARα agonist GW alone
reduces the TNF-induced p65 recruitment at this inflammatory
promoter, however, single DEX or combinedDEX/GW treatment
clearly does not affect TNF-induced promoter occupation of
p65. When analyzing concomitant GR occupancy under the
same conditions, DEX treatment consistently increases GR
recruitment at the IL8 promoter (Figure 5B). When combined
with TNF, DEX supports even more GR recruitment (Figure 5B,
compare lanes 2 and 6). Of note, additional GW treatment
does not further affect GR recruitment (Figure 5B, lane 8). In
concordance with the results on gene repression (Figure 1),
we detect lower IL8 promoter occupancy of RNA polymerase
II (RNA pol II) when combining DEX, GW or DEX/GW
as compared to TNF alone (Figure 5C). The combination of
DEX/GW with TNF did however not result in a lower IL8
promoter occupancy of RNA pol II as compared to DEX/TNF,
or GW/TNF alone. Lower levels of RNA pol II recruitment upon
GW/TNF (Figure 5C) nicely correlate with a lower level of p65
recruitment upon GW/TNF (Figure 5A), yet again the effect of
DEX, and additional presence of GR (Figure 5B) is dominant.
Taken together, these results show that even though MSK1
activation is reduced (Figure 3B), still, p65 is not dissociated
from the IL8 promoter under conditions of a maximal pro-
inflammatory gene inhibition by DEX and PPARα agonists.
PPARα and GRα Interact With NF-κB p65 in
a Non-competitive Manner in vitro
The underlying mechanism as suggested by the transcriptional
data (Figure 1) and the ChIP results (Figure 5) may involve
either tethering events or independent DNA binding events.
Direct interactions between single GR or single PPARα with the
p65 subunit of NF-κB were previously reported to contribute
to the inhibition of NF-κB-dependent pro-inflammatory gene
expression and were described to involve (a) the DNA binding
domain of either GRα or PPARα and (b) the Rel Homology
Domain (RHD) of p65 (33, 39, 40). To obtain further insight
into the molecular basis of the additive anti-inflammatory effect
observed upon combining GR and PPARα agonists, we tested
whether GRα and PPARα are able to bind p65 simultaneously
or instead in a competitive and mutually exclusive manner. Since
both receptors have been described to interact with largely similar
domains within p65 (AA 22-248 and 12-378 for GRα and PPARα,
respectively (33, 39, 40), the possibility of a competitive and
independent binding was considered.
GST-pull down experiments show that binding between GST-
PPARα and in vitro produced GRα (35S) can be outcompeted by
Frontiers in Immunology | www.frontiersin.org 8 August 2019 | Volume 10 | Article 1769
Bougarne et al. PPARα/GRα Crosstalk Targets MSK1
FIGURE 7 | Co-activation of GRα and PPARα enhances lipid metabolism gene subsets and lowers stress response gene subsets in LPS-induced primary
hepatocytes. (A) Schematic overview of the RNA-seq experiment (n = 3). (B) Heatmap using K-mean clustering of 3,441 differentially expressed genes from contrasts
(p adjusted < 0.05): LPS (100 ng/ml) vs. DEX+LPS, LPS vs. GW+LPS, LPS vs. DEX/GW+LPS, DEX+LPS vs. DEX/GW+LPS and GW+LPS vs. DEX/GW+LPS.
Color scale represents gene counts. (C) Gene ontology analysis of differentially upregulated (clusters 2 and 3) and downregulated (cluster 5) genes by DEX/GW vs.
LPS, DEX and GW.
cold GRα (Figure 6A, quantification see Figure S5A), illustrating
the feasibility to detect competitive binding in a GST-pull
down assay and supporting our previous findings, via co-
IP, that PPARα and GRα indeed physically interact (22).
The interaction between GST-PPARα and in vitro produced
p65 (35S) is however not affected by increasing amounts of
GRα (35S) (Figure 6B, quantification see Figure S5B). Similarly,
adding increasing amounts of p65 (35S) also does not affect
the binding between GST-PPARα and in vitro produced GRα
(35S) (Figure 6C, quantification see Figure S5C). Altogether, our
GST-pull down experiments support that GR and PPARα may
interact with the RHD of p65 in a non-competitive manner,
supporting the hypothesis of complex formation between all
three transcription factors.
The in vitro experiments cannot take into account the
possibility that the single ligand treatments and/or co-treatments
may additionally affect receptor protein expressions in a cellular
environment. To address this extra parameter, A549 cells were
pretreated with solvent, DEX (1mM), GW (0.5µM) or various
combinations for 1 h, before TNF (2000 IU/ml) was added for
a total induction time of 6 h (to match the time points in
Figure 1). Interestingly, the results from Figure S6 show that in
inflamed cells (last 4 lanes, with TNF added) the combined ligand
treatment DEX/GW is capable of lowering not only protein
levels of the pro-inflammatory protein p65, but concomitantly
also of both receptor levels. Strikingly, GW/DEX alone largely
recapitulated the effect observed of both ligands in presence of
TNF. Similar data were found for a shorter time point (1.5 h)
(Figure S7), albeit not as outspoken. These findings nevertheless
support the validity of the findings presented in Figure S6.
GR and PPARα Co-regulate Lipid
Metabolism and Inflammatory Gene
Expression in Opposite Manners in
Inflamed Murine Hepatocytes
When looking at the broader picture of possible target cells,
GCs and PPARα will not only regulate genes in immune or
structural cell types coping with an inflammatory insult (e.g.,
synovial fibroblasts, macrophages, T-cells, or lung epithelial cells
as studied here), but will also trigger gene programs in metabolic
tissues, such as hepatocytes. Activated GR and PPARα have
been described before to additively upregulate a vast subset of
key genes of the lipid metabolism pathway in naïve murine
primary hepatocytes (21). Combined ligand treatment was
shown to exhibit anti-inflammatory capacities in lung epithelial
cells as typical effector cells contributing to an inflammatory
response (Figure 1), but it remained uncertain whether primary
hepatocytes would behave in a similar manner, given a dominant
role of GR/PPARα in glucose and fat metabolism in this cell
type. To address this question, we performed RNA-seq following
DEX and GW co-treatment for 19 h in presence of LPS to
additionally mimic an inflamed state (Figure 7A). K-means
clustering following the differential expression analysis revealed
992 genes (Figure 7B, cluster 2 and 3) upregulated by the
combination of DEX/GW with LPS treatment compared to
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FIGURE 8 | Co-activation of GRα and PPARα additively lowers inflammatory gene and protein expression in LPS-induced primary hepatocytes. Results are shown for
mRNA (A) and protein (B) levels. (A) Following the treatment of primary hepatocytes as described in the legend of Figure 6, mRNA was isolated followed by qPCR
analysis. Gene expression levels were normalized to Ppia/cyclophilin and Gapdh reference gene expression using qbase+ (n = 4–5). (B) CCL2 and IL6 ELISA from the
media of primary hepatocytes after 19 h treatment with DEX (1µM) and GW (0.5µM) in combination with 100 ng/ml LPS (n = 3). Statistical analysis was done using
1-way ANOVA and Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). NI, non-induced.
LPS alone. Among those, 132 genes were significantly more
upregulated when compared to each compound alone (DEX +
LPS or GW + LPS). Gene ontology analysis of these 132 genes
attributed them to the lipid metabolism pathway (Figure 7C).
This was consistent with previous results obtained in a basal state
(21). LPS treatment did not influence DEX/GW-co-regulated
gene expression in primary hepatocytes of one of the key
co-controlled genes, Angptl4; a result that was independently
validated by qPCR (Figure S8). We detected also 279 genes
downregulated by DEX/GW + LPS treatment compared to LPS
(Figure 7B, cluster 5). Only 34 of those were significantly more
repressed upon comparing with either DEX+ LPS or GW+ LPS
treatment alone. Some of these genes are inflammatory markers
such as Icam1, Ikbke, Nfkb2, Mapk3, Tlr2.
GR and PPARα Cooperate to Downregulate
Inflammatory Genes and Proteins in
Inflamed Murine Hepatocytes
The results were next validated using qPCR in independently
isolated murine primary hepatocytes (Figure 8A). We also
determined mRNA levels of the classic inflammatory marker
Ccl2. Similar to mRNA results, the protein levels of CCL2 were
suppressed by combined DEX/GW treatment in presence of
the inflammatory stimulus when compared to each compound
alone (Figure 8B). Although the overall expression levels of
IL6 in LPS-induced hepatocytes were almost two orders of
magnitude lower than of CCL2 levels, we still observed a similar
regulation (Figure 8B). Taken together, in analogy with the TNF-
induced lung epithelial cell model, simultaneous GR and PPARα
activation also supports additive anti-inflammatory effects in the
LPS-inflamed primary hepatocyte model.
DISCUSSION
The activation of PPARα was shown before to suppress the
induction of liver gluconeogenic G6PC and PEPCK genes that
were activated by GR in mice subject to a high fat diet (22).
As such, combined PPARα and GRα agonist treatment might
hold a promise of therapeutic benefit when able to cooperatively
enhance anti-inflammatory effects, while circumventing (at least)
the side effect of GC-induced glucose intolerance. In the current
research we studied the GRα-PPARα crosstalk paradigm and its
putative role in the transcriptional regulation of inflammatory
genes comparing two cell types in which both GRα and PPARα
are well-expressed and functional, i.e., hepatocytes and lung
epithelial cells. We demonstrated that simultaneous GRα-PPARα
activation additively suppresses inflammation both in LPS-
treated murine primary hepatocytes and TNF-induced human
lung epithelial cells. In the latter cell type, we went on to
show via Western analysis using phospho-specific antibodies,
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FIGURE 9 | GRα/PPARα controlled points of interference with the TNF signaling pathway. Graphical abstract demonstrating activated GRα/PPARα efficiently inhibits
TNF-driven gene expression in A549 cells primarily by interfering with the phosphorylation status of MSK1. Signaling components of the NF-κB pathway that have
been studied in the manuscript are shown in non-gray colors. GR, Glucocorticoid Receptor α; IKK, IκB kinase, MAPK, Mitogen-activated protein kinase; MKK, MAP
kinase kinase; PPAR, peroxisome proliferator activated receptor α; TNF, tumor necrosis factor; TNFR, TNF receptor.
that GR-PPARα crosstalk may block inflammatory cytokine
gene expression in the nucleus by mitigating the activity of
a kinase upstream of NF-κB, MSK1, but not its upstream
MAPK activators. This mechanism seems in contrast with
a recently described mechanism in macrophages, explaining
anti-inflammatory effects of single GCs not solely via gene
suppression but through cooperative actions with p38 MAPK-
andMSK1-dependent pathways, culminating in the upregulation
and activation of another kinase, Sphingosine kinase 1 (SphK1)
(41). However, these mechanisms do not necessarily exclude
each other and are likely complementary. Indeed, it is not
unreasonable to infer that different GC-assisted mechanisms
may come in at different phases of the inflammatory response,
or that in different cell types GCs may preferentially impact
at different levels to establish a net anti-inflammatory effect.
From our data, both GCs and PPARα agonist alone are able
to partially drive MSK1 kinase from the nucleus, confirming
earlier findings for GCs (23). At any rate, the finding that
the subcellular distribution of MSK1 upon DEX/GW/TNF is
similar to DEX/TNF implies that extrusion by itself is probably
not a main mechanism explaining the additive gene repression.
Rather, inhibition of MSK1 activation, which will hamper
MSK1 activity, and interference at the level of NF-κB further
downstream seem sufficient mechanisms to achieve additive
cytokine gene repression (model in Figure 9). Taken together,
it is clear that anti-inflammatory pathways that jointly tackle
pathways leading to NF-κB activity will have an added advantage,
as also found before in a study combining GCs with MSK1
inhibitors (42). Of interest from a clinical perspective, increased
levels of activated MSK1 were detected in circulating blood
CD14+ cells from patients with steroid-resistant asthma as
compared to samples from steroid-sensitive asthma patients,
linking a potential involvement of MSK1 in the regulation of
cellular steroid responses (43). In a recent study in support
of combination strategies, the team of Goleva showed benefit
upon combining GCs with vitamin D, by demonstrating anti-
inflammatory and GC-enhancing effects inmonocytes of patients
not only in steroid-sensitive asthma but also to some extent in
steroid-resistant asthma (44).
We found that combined DEX/GW was able to reduce not
only GRα and PPARα protein levels but also p65, in absence
and presence of TNF. Regardless, inflammatory gene repression
by combined GRα-PPARα agonists (studied here at the human
IL8 promoter) was found to still involve maintaining the p65
subunit of NF-κB as well as GRα and PPARα at the chromatin
(model in Figure 9). This finding apparently contrasts a study
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in macrophages showing GR activation, on its own, results in
genome-wide blockade of NF-κB interaction with chromatin,
as a late GC-induced event when inflammatory responses are
allowed to fully mount (45). Again, this is not necessarily in
conflict, as our study rather brings forward mechanisms likely
to occur when GCs are ahead of a full-blown inflammatory
response. In support of our data, in another recent study on
mouse macrophages GR was rather shown to suppress pro-
inflammatory gene expression by targeting distinct temporal
events and components of transcriptional machinery in a gene-
dependent manner, yet, the mechanism consistently involved
a rapid GR tethering to p65 at NF-κB-binding sites (46). Our
findings, adding PPARα to the equation, make it tempting
to suggest a tripartite physical interaction mechanism may be
possible. In line herewith, we retrieve all activated proteins (p65,
GR, and PPARα) in the nuclear compartment, when performing
pairwise indirect immunofluorescence of endogenous proteins
in A549. Support for a physical interaction between p65, GRα
and PPARα, at least in vitro, was found through non-competitive
associations in GST-pull down analyses. Our data only shed light
on a little piece of the anti-inflammatory mechanism following
combined action of GRα and PPARα. Combined GRα/PPARα
treatment reduces MSK1 kinase activation and appears to change
the balance between nuclear vs. cytoplasmic MSK1, perhaps
by preventing the accessibility of the kinase to the NF-κB
target. Although these events clearly do not affect promoter
recruitment of p65 or of pol II, at least not for IL8, a change
in the activity status of NF-κB may well change coregulator
associations, leading to a negative impact on gene expression. The
in vitro interaction data, involving bacterial proteins and in vitro
translated protein, suggest GR/PPAR/p65 complex formation, at
least in vitro, might not be dependent on phosphorylation events,
which is supported by the finding from the cell data that activated
p65 remains efficiently recruited in presence of co-activated
GRα/PPARα. It remains to be studied however, how frequent
GRα and PPARα may co-localize in the cell models we have
presented here, when subject to an inflammatory stimulus. In
addition, direct proof of in cellulo complex formation at relevant
promoter regions awaits firm evidence, for instance upon using
re-ChIP experiments. Also the nature of the predominant
binding sites remains to be investigated (half-site or palindromic
GRE vs. PPRE vs. NF-κB response elements). In line with a
previously recognized role for GRIP1 acting as a corepressor
contributing to the suppressive action of GR (47–49), it is of
current also unclear which cofactors may differentially associate
with the GRα/PPARα co-suppressed inflammatory promoters as
compared to either stimulus alone. On the physiological side,
follow-up studies will have to demonstrate a predicted improved
therapeutic benefit may take place, when co-administering GCs
and PPARα agonists in an animal model of chronic inflammation
(e.g., multiple sclerosis, arthritis, or asthma). Such study will
allow simultaneous evaluation of the anti-inflammatory activity
in relevant inflammatory target cells (depending on the animal
model) with a metabolic impact addressing responses of the
liver, regulating glucose and fat metabolism, when allowed to
communicate with the other endocrine tissue within a complex
organism under chronic inflammatory pressure.
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Figure S1 | (Quantification Figure 2A). Western blot densitometric analysis. The
P-IKK band (upper panel) and IκBα band (Lower panel) visualized via Western blot
analysis in Figure 2A were subjected to band densitometric analysis using Image
J. The amount of specific signal for P-IKK and IκBα was corrected to the
respective tubulin loading control.
Figure S2 | (Quantification Figures 3A,B). Western blot densitometric analysis.
(A) The phospho-MAPK bands visualized via Western blot analysis in Figure 3A
were subjected to band densitometric analysis (Image J). The amount of specific
signal for phospho-MAPK was corrected to the respective corresponding
non-phospho-MAPK signal. (B) The phospho-MSK1 bands visualized via Western
blot analysis in Figure 3B were subjected to band densitometric analysis using
Image J. The amount of specific signal for the phospho-MSK1 was corrected to
the respective non-phospho-MSK1.
Figure S3 | Ligand-activated GRα and p65 are both localized in the nucleus in
TNF-stimulated cells. (A) A549 cells, starved for 48 h in DMEM devoid of serum,
were pretreated with solvent, DEX (1µM), GW (0.5µM) or various combinations
for 1h, before TNF (2000 IU/ml) was added, where indicated, for 30min.
Localization of p65 (green) and GRα (red) was assessed by confocal analysis.
DAPI staining indicates the nuclei of the cells (blue). Immunofluorescence of
representative cell fields is shown (n = 1). (B) Per induction, minimally three
random fields of minimally 5 cells/field were scored. Scored cells are categorized
into three groups according to the subcellular distribution of p65 (green) and GRα
(red), i.e., C, mainly cytoplasmic; N, mainly nuclear; N/C, equally distributed
(nuclear/cytoplasmic).
Figure S4 | Ligand-activated PPARα and p65 are both localized in the nucleus in
TNF-stimulated cells. (A) A549 cells, starved for 48 h in DMEM devoid of serum,
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were pretreated with solvent, DEX (1µM), GW (0.5µM) or various combinations
for 1h, before TNF (2000 IU/ml) was added, where indicated, for 30min.
Localization of PPARα (green) and p65 (red) was assessed by confocal analysis.
DAPI staining indicates the nuclei of the cells (blue). Immunofluorescence of
representative cell fields is shown (n = 1). (B) Per induction, minimally three
random fields of minimally 5 cells/field were scored. Absolute amounts of cells that
were scored per induction were between 30 and 65 cells and categorized into
three groups according to the subcellular distribution of PPARα (green) and p65
(red), i.e., C, mainly cytoplasmic; N, mainly nuclear; N/C, equally distributed
(nuclear/cytoplasmic).
Figure S5 | (Quantification Figures 6A–C). GST pull down analysis. (A)
[35S]-methionine labeled GRα pull down and (B,C) [35S]-methionine labeled p65
and [35S]-methionine labeled GRα pull down visualized via autoradiography in
Figure 5 were quantified using ImageJ analysis. Signals were normalized against
respective inputs.
Figure S6 | Combined PPARα/GRα activation diminishes p65 levels as well as
nuclear receptor levels following 6h inductions, in absence and presence of TNF.
(A) A549 cells, starved for 48 h in DMEM devoid of serum, were pretreated with
solvent, DEX (1µM), GW (0.5µM) or various combinations for 1h, before TNF
(2000 IU/ml) was added, where indicated, for a total induction time of 6h. Cell
lysates were subjected to western blotting to detect GRα, PPARα or p65.
Detection of β-actin served as a loading control. n = 1. (B) The bands visualized
via Western blot analysis were subjected to band densitometric analysis using
Image J. The amount of specific signal for was corrected to the respective actin
loading control.
Figure S7 | Combined PPARα/GRα activation already diminishes p65 levels as
well as nuclear receptor levels following 1.5 h inductions, in absence and presence
of TNF. (A) A549 cells, starved for 48 h in DMEM devoid of serum, were pretreated
with solvent, DEX (1µM), GW (0.5µM) or various combinations for 1 h, before TNF
(2000 IU/ml) was added, where indicated, for a total induction time of 1.5 h. Cell
lysates were subjected to western blotting to detect GRα, PPARα or p65.
Detection of β-actin served as a loading control. n = 1. (B) The bands visualized
via Western blot analysis were subjected to band densitometric analysis using
Image J. The amount of specific signal was corrected to the respective actin
loading control.
Figure S8 | Co-activation of GRα and PPARα enhances the lipid metabolism gene
Angptl4. Gene counts for Angptl4 upon DEX (1µM), GW (0.5µM) and LPS
(100ng/ml) treatment of primary hepatocytes, from the experiment described in
Figure 7. n = 1. Bars represent mean+SEM. NI, non-induced.
Table S1 | List of qPCR primers.
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